Last week was not so good for new stocks. Eight deals were on tap but only six could get done. In fact, two of the offerings posted negative returns and another broke even. Source: ©iStock.com/zigarrenschachtel
As has been the case for the past few months, the most trouble came from biotech offerings. It appears that there have been just too many deals — and yes, investors are getting much more selective.
How about this week? Well, there are no biotechs on the calendar. However, there are a spattering of other new stocks that plan to come public. Read